13F Holdings
中文EN

ABOS Acumen Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1576885 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY22.0%
TTM EPS YoY29.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-162.7%
ROA-91.3%
ROIC (approx.)-195.6%
Asset turnover—

Leverage & solvency

Liabilities / assets59.6%
Debt / equity0.76x
Current ratio1.89x
Interest coverage-24.65x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$21.11M$27.81M$16.48M$20.53M$21.97M$37.12M$25.27M$34.57M
SG&A expense$4.70M$4.75M$4.67M$4.67M$4.54M$4.62M$5.10M$5.03M
Operating income-$25.81M-$32.56M-$21.15M-$25.20M-$26.51M-$41.75M-$30.37M-$39.60M
Interest expense$999,000$1.09M$1.07M$1.09M$1.07M$1.05M$1.02M$1.04M
Net income-$25.37M-$32.72M-$20.74M-$25.14M-$26.45M-$40.95M-$28.80M-$37.15M
EBITDA-$25.80M-$32.55M-$21.14M-$25.19M-$26.50M-$41.73M-$30.36M-$39.58M
EPS (basic)-0.35-0.45-0.33—-0.44-0.68-0.48—
EPS (diluted)-0.35-0.45-0.33—-0.44-0.68-0.48—
Weighted avg. shares (diluted)72.32M72.25M63.22M—60.57M60.57M60.53M—
Balance sheet
Cash & equivalents$53.08M$59.44M$51.80M$53.99M$47.06M$37.04M$30.39M$35.86M
Short-term investments$25.53M$50.75M$76.60M$62.88M$79.78M$106.56M$118.99M$135.93M
Current assets$85.13M$115.51M$133.09M$122.25M$132.15M$148.40M$154.95M$178.31M
PP&E, net$68,000$80,000$91,000$103,000$115,000$130,000$137,000$73,000
Total assets$85.56M$116.01M$133.63M$122.83M$142.22M$171.90M$204.48M$238.99M
Current liabilities$45.09M$46.85M$29.23M$30.01M$21.96M$24.86M$19.32M$27.61M
Short-term debt$20.40M$19.67M$14.12M$8.77M$3.60M——$0
Long-term debt$5.87M$11.90M$16.92M$22.40M$27.05M$29.88M$29.53M$29.42M
Total debt$26.27M$31.57M$31.05M$31.16M$30.65M$29.88M$29.53M$29.42M
Total liabilities$50.95M$58.74M$46.15M$52.40M$49.05M$54.82M$48.96M$57.18M
Shareholders' equity$34.61M$57.26M$87.48M$70.43M$93.17M$117.08M$155.52M$181.82M
Net debt-$26.80M-$27.87M-$20.75M-$22.83M-$16.41M-$7.16M-$863,000-$6.44M
Shares outstanding72.33M72.31M72.23M60.58M60.57M60.57M60.57M60.09M
Cash flow statement
Operating cash flow-$26.65M-$18.07M-$24.13M-$19.10M-$30.49M-$31.83M-$34.12M-$27.21M
Capital expenditure$0$0$0$0$0$9,000$79,000$0
Free cash flow-$26.65M-$18.07M-$24.13M-$19.10M-$30.49M-$31.84M-$34.20M-$27.21M
Investing cash flow$25.25M$26.00M-$13.81M$26.25M$40.51M$38.48M$28.69M$29.66M
Financing cash flow-$4.96M-$278,000$35.74M$2,000$0$0-$36,000-$9,000
Depreciation & amortization$12,000$11,000$12,000$12,000$15,000$16,000$15,000$14,000
Stock-based compensation$2.71M$2.52M$2.40M$2.42M$2.46M$2.50M$2.47M$2.34M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.